Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    0.00 (0.00%)
Bid:
0.18
Ask:
0.19
Spread: 0.01 (5.556%)
Market Cap: £1.37m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Convertible Loan Note Offer

18 Jul 2006 15:48

Azure Holdings PLC18 July 2006 Azure Holdings plc (the "Company") Convertible Loan Note Offer The Company announces that it has today issued a letter to holders of ordinaryshares of 1p each in the Company ("Ordinary Shares"), on the share register ofthe Company on 17 July 2006, offering them the opportunity to participate in thesubscription of up to £1,200,000 nominal unsecured convertible loan stock 2008("Loan Stock"). The Loan Stock is being offered following discussions regarding a proposedacquisition by the Company ("Acquisition"). The proposed target for theAcquisition is ValiRX Limited ("ValiRX"), a biopharmaceutical developmentcompany. Discussions with ValiRX are progressing and the directors of theCompany hope to complete a reverse takeover under the AIM rules before 30September 2006. The principal terms of the Loan Stock are as follows: 1 Unless previously converted or repaid, the Loan Stock isrepayable 24 months from the date of the Loan Stock instrument under which it iscreated (the "Instrument") or at any time after 31 October 2006 at the Company'soption. 2 In partial consideration for the Loan Stock holderssubscribing for Loan Stock, a premium ("Premium") of £2 for each £1 nominal ofLoan Stock is payable, unless previously converted or paid, 24 months from thedate of the Instrument, or at any time after 31 October 2006 at the Company'soption. 3 Interest is payable from 1 November 2006 on the amount ofthe Loan Stock at the rate of two per cent. over the base rate of the Bank ofScotland plc from time to time. Interest is payable twice yearly. The firstinterest period will run from 1 November 2006 to 31 March 2007. 4 The conversion of Loan Stock ("Conversion") into OrdinaryShares is conditional upon approval by shareholders of resolutions to allotshares and disapply pre-emption rights; and if appropriate, the approval by avote of independent shareholders taken on a poll of any waiver granted by thePanel on Takeovers and Mergers of any obligation under rule 9 of the City Codeon Takeovers and Mergers which may arise from such Conversion (together the "Conversion Event") 5 Immediately prior to the Conversion Event, the Loan Stockis deemed repayable and the Premium is deemed payable. 6 On the Conversion Event, the Loan Stock and the Premiumwhich has not been repaid or paid as the case may be, will be converted intoOrdinary Shares in the capital of the Company at the rate of 100 Ordinary Sharesof the Company for each £1 otherwise due for repayment or payment. 7 So far as it is lawfully able to do so, the Company willnotify the Loan Stock holders at least 10 days in advance of the likelyoccurrence of the Conversion Event. 8 The Loan Stock is transferable in multiples of £10,000. 9 The Company is obliged to repay the Loan Stock and pay thePremium on the occurrence of certain events, including certain insolvencyevents. 10 Decisions relating to the Loan Stock are to be taken by a writtenresolution of the holders of at least two thirds in nominal value of theoutstanding Loan Stock. Applications for the Loan Stock may only be made for a minimum of £1,000 nominaland in multiples of £1,000. Applications for the Loan Stock are to be receivedby the Company at One Great Cumberland Place, London W1H 7AL by 3.00pm on 31July 2006. A copy of the letter despatched to shareholders and the Instrument are availablefor inspection, on request, at Halliwells LLP, 1 Threadneedle Street, LondonEC2R 8AW during normal business hours on any weekdays, Saturdays, Sundays andpublic holidays excluded, for one month from today. For further information, please contact: Barry Gold, Azure Holdings plcTel: 07768 948 928 David Youngman, WH Ireland Limited Tel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Jul 202210:46 amRNSHolding(s) in Company
13th Jul 20222:15 pmRNSSuccessful evaluation of breast cancer programme
7th Jul 202211:07 amRNSDirector/PDMR Shareholding
5th Jul 202211:45 amRNSHolding(s) in Company
5th Jul 20227:00 amRNSBroker Option Results
30th Jun 20223:00 pmRNSResult of AGM and Appointment of Joint Broker
30th Jun 202210:31 amRNSIssue of Equity
30th Jun 202210:30 amRNSExtends exclusivity period for TheoremRx
17th Jun 202210:01 amRNSUpdate on VAL201 sub-license agreement
7th Jun 20224:33 pmRNSAnnual Report, AGM Notice & Director Resignation
23rd Mar 20227:00 amRNSUpdate on proposed sub-license of VAL201
15th Mar 20227:00 amRNSOperational and Strategy Update
14th Feb 20227:00 amRNSEvaluation agreement with University of Barcelona
5th Jan 20224:41 pmRNSSecond Price Monitoring Extn
5th Jan 20224:36 pmRNSPrice Monitoring Extension
5th Jan 20222:06 pmRNSSecond Price Monitoring Extn
5th Jan 20222:00 pmRNSPrice Monitoring Extension
5th Jan 202211:00 amRNSPrice Monitoring Extension
5th Jan 20229:06 amRNSSecond Price Monitoring Extn
5th Jan 20229:00 amRNSPrice Monitoring Extension
5th Jan 20227:16 amRNSSigns Service Agreement with TheoremRx
20th Dec 20217:00 amRNSAmends License for VAL201 with CRT
16th Dec 202110:46 amRNSEvaluation agreement with Hokkaido University
11th Nov 20217:00 amRNSLive Shareholder Q&A and Investor presentations
8th Nov 20213:03 pmRNSHolding(s) in Company
2nd Nov 20217:00 amRNSSigns Letter of Intent to Sub-License VAL201
26th Oct 20212:00 pmRNSPrice Monitoring Extension
26th Oct 202111:05 amRNSSecond Price Monitoring Extn
26th Oct 202111:00 amRNSPrice Monitoring Extension
26th Oct 20217:00 amRNSHolding(s) in Company
20th Oct 20211:19 pmRNSHolding(s) in Company
19th Oct 202112:23 pmRNSHolding(s) in Company
18th Oct 20214:41 pmRNSSecond Price Monitoring Extn
18th Oct 20214:36 pmRNSPrice Monitoring Extension
18th Oct 20212:06 pmRNSSecond Price Monitoring Extn
18th Oct 20212:01 pmRNSPrice Monitoring Extension
18th Oct 202111:06 amRNSSecond Price Monitoring Extn
18th Oct 202111:00 amRNSPrice Monitoring Extension
30th Sep 20212:45 pmRNSHolding(s) in Company
30th Sep 202112:24 pmRNSHolding(s) in Company
28th Sep 20214:41 pmRNSSecond Price Monitoring Extn
28th Sep 20214:36 pmRNSPrice Monitoring Extension
17th Sep 20214:41 pmRNSSecond Price Monitoring Extn
17th Sep 20214:36 pmRNSPrice Monitoring Extension
16th Sep 20217:00 amRNSNew Evaluation Agreement
8th Sep 20217:00 amRNSHolding(s) in Company
7th Sep 20217:00 amRNSHalf-year Report
25th Aug 20217:00 amRNSAppointment of Broker
20th Aug 20212:05 pmRNSSecond Price Monitoring Extn
20th Aug 20212:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.